| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| January 14, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 17,083 | -- | 17,083 | |
| January 14, 2011 | CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 17,083 | -- | 17,083 | |
| May 30, 2017 | Controller | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 17,143 | -- | 17,143 | |
| March 5, 2018 | Director, Chairman, President and CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 7,500 | $2.38 | 17,700 | |
| March 15, 2006 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 3,676 | -- | 17,876 | |
| March 3, 2006 | EVP, CFO | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,500 | $4.28 | 17,944 | |
| March 6, 2019 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,300 | $2.13 | 18,050 | |
| September 20, 2018 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,500 | $2.70 | 18,091 | |
| December 22, 2003 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 18,349 | -- | 18,349 | |
| March 17, 2023 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 2,000 | -- | 18,429 | |
| October 3, 2006 | VP of Research & Development | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,100 | -- | 18,434 | |
| September 20, 2012 | Director | Form 4 | Exercise of in-the-money or at-the-money derivative security | 34,542 | $2.77 | 18,735 | |
| September 14, 2012 | SVP Corp Bus Strategy/IR | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,000 | $4.93 | 18,787 | |
| February 26, 2014 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 4,500 | $3.72 | 18,831 | |
| January 19, 2009 | VP & Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,000 | $2.72 | 19,000 | |
| March 4, 2022 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 7,500 | -- | 19,742 | |
| February 2, 2016 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 12,000 | $1.33 | 19,926 | |
| March 15, 2024 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 3,500 | -- | 19,930 | |
| December 7, 2023 | Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | -- | 20,000 | |
| February 22, 2018 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 7,143 | $2.17 | 20,000 | |
| November 15, 2005 | VP of Operations | Form 4 | Open market or private purchase of non-derivative or derivative security | 20,000 | $0.31 | 20,000 | |
| March 15, 2006 | VP - Operations | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 3,500 | -- | 20,167 | |
| April 9, 2018 | Director, Chairman, President and CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,500 | $2.30 | 20,200 | |
| June 30, 2016 | Director | Form 4 | Other acquisition or disposition (describe transaction) | 7,539 | $1.27 | 20,215 | |
| June 20, 2014 | CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,500 | $3.50 | 20,228 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.
